Activation of EGFR [46] promotes proliferation, invasion, angiogenesis, and metastasis [47,48] EGFR is overexpressed in up to 90% of primary HNSCC [45] and is the target of several types of drugs which block ligand binding, inhibit EGFR tyrosine kinases or induce antibody dependent cellular cytotoxicity. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.